Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ventyx Biosciences, Inc.

3.56
-0.3000-7.77%
Post-market: 3.50-0.0600-1.69%18:55 EDT
Volume:1.47M
Turnover:5.33M
Market Cap:253.86M
PE:-2.12
High:3.88
Open:3.86
Low:3.48
Close:3.86
52wk High:4.05
52wk Low:0.7830
Shares:71.31M
Float Shares:53.56M
Volume Ratio:0.89
T/O Rate:2.75%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6773
EPS(LYR):-1.9732
ROE:-48.56%
ROA:-30.23%
PB:1.21
PE(LYR):-1.80

Loading ...

Dec 16, 2022

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
Dec 15, 2022

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
Dec 12, 2022

Major Issues Report

8-K - Current report
Nov 30, 2022

Major Issues Report

8-K - Current report
Nov 09, 2022

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
Nov 04, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 03, 2022

Major Issues Report

8-K - Current report
Sep 30, 2022

Correspondence

CORRESP [Cover] - Correspondence
Sep 27, 2022

Public Prospectus

S-1 - General form for registration of securities under the Securities Act of 1933
Sep 21, 2022

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
Sep 19, 2022

Major Issues Report

8-K - Current report
Sep 14, 2022

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
Aug 15, 2022

Major Issues Report

8-K - Current report
Aug 15, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Jun 29, 2022

Major Issues Report

8-K - Current report
Jun 09, 2022

Major Issues Report

8-K - Current report
May 12, 2022

Major Issues Report

8-K - Current report
May 12, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
May 09, 2022

Major Issues Report

8-K - Current report
Mar 24, 2022

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]